White House officials told governors during their weekly call that there won't be any doses of Johnson & Johnson's vaccine in next week's federal allocations, according to an official familiar with the matter.
The move is another sign of the repeated problems that have plagued J&J's rollout in the US. Officials had once hoped it would be key to quick vaccinations, given it requires only one dose compared to the others that require two. But J&J has faced multiple issues, including limited shipments and a brief pause to evaluate a link to rare blood clots.
Most problems have stemmed from a production plant in Baltimore that ruined 15 million potential J&J vaccines earlier this year due to poor quality control and contamination of vaccine ingredients. That facility, which is run by Emergent BioSolutions and is still awaiting FDA authorization, has come under increasing scrutiny after a report by the FDA detailed multiple flaws, including that there was "no assurance that other batches have not been subject to cross-contamination."
Two of Emergent BioSolutions' executives have now agreed to testify on Capitol Hill next week.
Rep. Jim Clyburn told CNN Wednesday morning there appeared to be "untoward" events taking place and said the House's select committee on the coronavirus was looking at the two executives, Fuad El-Hibri and Robert Kramer.
"They all made millions in stock transactions while they seem to be hiding stuff from the public," Clyburn said. "So we want to make sure that no laws were broken. Certainly we don't know that yet."